Active Ingredient History

  • Now
Galeterone is a steroidal antiandrogen which was under development by Tokai Pharmaceuticals for the treatment of prostate cancer. It possesses a unique triple mechanism of action, acting as an androgen receptor antagonist, androgen receptor down regulator, and CYP17A1 inhibitor, the latter of which prevents the biosynthesis of androgens. As a CYP17A1 inhibitor, galeterone shows selectivity for 17,20-lyase over 17α-hydroxylase.   Wikipedia

  • SMILES: C[C@]12CC[C@H]3[C@@H](CC=C4C[C@@H](O)CC[C@]34C)[C@@H]1CC=C2n5cnc6ccccc56
  • Mol. Mass: 388.56
  • ALogP: 5.81
  • ChEMBL Molecule:
More Chemistry
17-(1h-benzimidazol-1-yl)androsta-5,16-dien-3beta-ol | 3beta-hydroxy-17-(1h-benzimidazole-1-yl)androsta-5,16-diene | 3-hydroxy-17-(1h-benzimidazole-1-yl)androsta-5,16-diene | galeterone | tok-001 | vn/124 | vn-124-1 | vn/124-1


Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue